Tislelizumab
Tislelizumab is a monoclonal antibody used in the treatment of various types of cancer. It is specifically designed to target and inhibit the programmed cell death protein 1 (PD-1) pathway, which is a mechanism that tumors use to evade the immune system.
Mechanism of Action[edit]
Tislelizumab works by binding to the PD-1 receptor on T cells, a type of white blood cell that plays a crucial role in the body's immune response. By inhibiting the interaction between PD-1 and its ligands, PD-L1 and PD-L2, tislelizumab enhances the immune system's ability to detect and destroy cancer cells.
Indications[edit]
Tislelizumab is approved for the treatment of several types of cancer, including:
Clinical Trials[edit]
Tislelizumab has undergone extensive clinical trials to evaluate its efficacy and safety. These trials have demonstrated significant anti-tumor activity and manageable safety profiles in patients with various types of cancer.
Side Effects[edit]
Common side effects of tislelizumab include:
Serious side effects may include immune-related adverse events such as pneumonitis, hepatitis, colitis, and endocrinopathies.
Development and Approval[edit]
Tislelizumab was developed by BeiGene, a global biotechnology company. It has received approval from regulatory agencies in several countries for the treatment of specific types of cancer.
See Also[edit]
References[edit]
External Links[edit]
 | This medical article is a stub. You can help WikiMD by expanding the page. |
